Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Shionogi's S-217622 is an oral antiviral like Pardes' PBI-0451. Both of these inhibit the CoV main protease (3CL, MPro), just like brilacidin is predicted to do.

So there will be two more pills (same target) besides molnupavir.

Pills or inhaled drug will be much easier to administer and probably more effective as antivirals since can be given early / outpatient.

IV antivirals like all the neutralizing antibodies, were not successful except in those at highest risk because it is so impractical to do IV infusions on outpatients.

By the time folks are admitted for Covid, they are probably mostly past the viral stage of disease, and more in need of immunomodulation / anti-inflammatory treatment. Hopefully brilacidin can bridge the gap/overlap between viral and immunological stages of Covid and find a nice niche there. It could be effective as both an antiviral and immunomodulatory/anti-inflammatory drug, not to mention it should help prevent bacterial pneumonia too.